Treg-mediated immune tolerance and the risk of solid cancers: Findings from EPIC-heidelberg

Journal of the National Cancer Institute

Volumn 107, Issue 11, 2015, Pages

  Barth, Sebastian Dietmar ^a   Schulze, Janika Josephine ^b   Kühn, Tilman ^a   Raschke, Eva ^b   Hüsing, Anika ^a   Johnson, Theron ^a   Kaaks, Rudolf ^a   Olek, Sven ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b EPIONTIS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GENOMIC DNA; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA DETERMINATION; DNA METHYLATION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; ICD-10; IMMUNOLOGICAL TOLERANCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; BREAST TUMOR; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL TUMOR; EUROPE; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTIGENS, CD3; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA METHYLATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 84946887780     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv224     Document Type: Article

References (51)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Cavallo F, De Giovanni C, Nanni P, et al. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011;60(3):319-326.
3. Galon J, Angell HK, Bedognetti D, et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11-26.
4. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T Cells and Immune Tolerance. Cell. 2008;133(5):775-787.
5. Sakaguchi S, Wing K, Yamaguchi T. Dynamics of peripheral tolerance and immune regulation mediated by Treg. Eur J Immunol. 2009;39(9):2331-2336.
6. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Sem Cancer Biol. 2006;16(2):115-123.
7. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380.
8. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949.
9. Flammiger A, Weisbach L, Huland H, et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2013;49(6):1273-1279.
10. Suzuki H, Chikazawa N, Tasaka T, et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother. 2010;59(5):653-661.
11. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
12. Rosenberg SA. Interleukin 2 for patients with renal cancer. Nat Clin Pract Oncol. 2007;4(9):497.
13. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107(6):2409-2414.
14. Jacobs JF, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13(1):e32-e42.
15. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006;103(17):6659-6664.
16. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110(8):2983-2990.
17. Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013;34(1):33-40.
18. Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55(9):1064-1071.
19. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423-5434.
20. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177(10):7398-7405.
21. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29(4):416-424.
22. Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65(6):2457-2464.
23. Hasegawa T, Suzuki H, Yamaura T, et al. Prognostic value of peripheral and local forkhead box P3 regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2(5):685-694.
24. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 2007;7:7.
25. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.
26. Baron U, Floess S, Wieczorek G, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur J Immunol. 2007;37(9):2378-2389.
27. Janson PC, Winerdal ME, Marits P, et al. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One. 2008;3(2):e1612.
28. Liu J, Lluis A, Illi S, et al. T regulatory cells in cord blood-FOXP3 demethylation as reliable quantitative marker. PLoS One. 2010;5(10):e13267.
29. Miyao T, Floess S, Setoguchi R, et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012;36(2):262-275.
30. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009;69(2):599-608.
31. Sehouli J, Loddenkemper C, Cornu T, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011;6(2):236-246.
32. Turbachova I, Schwachula T, Vasconcelos I, et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics. 2013;8(11):1226-1235.
33. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226-230.
34. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6b):1113-1124.
35. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPICGermany. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43(4):205-215.
36. Bergmann MM, Bussas U, Boeing H. Follow-up procedures in EPIC-Germany-data quality aspects. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43(4):225-234.
37. Langenberg C, Sharp S, Forouhi NG, et al. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia. 2011;54(9):2272-2282.
38. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73(1):1-11.
39. Xue X, Xie X, Gunter M, et al. Testing the proportional hazards assumption in case-cohort analysis. BMC Med Res Methodol. 2013;13:88.
40. Shimabukuro-Vornhagen A, Schlosser HA, Gryschok L, et al. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget. 2014;5(13):4651-4664.
41. Accomando WP, Wiencke JK, Houseman EA, et al. Decreased NK cells in patients with head and neck cancer determined in archival DNA. Clin Cancer Res. 2012;18(22):6147-6154.
42. Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795-1799.
43. Thomas AA, Fisher JL, Rahme GJ, et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol. 2015; In press.
44. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001;98(25):14565-14570.
45. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14(3):154-165.
46. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434(7031):400-404.
47. Hampras SS, Nesline M, Wallace PK, et al. Predictors of immunosuppressive regulatory T lymphocytes in healthy women. J Cancer Epidemiol. 2012;2012:191090.
48. Wiencke JK, Accomando WP, Zheng S, et al. Epigenetic biomarkers of T-cells in human glioma. Epigenetics. 2012;7(12):1391-1402.
49. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372-377.
50. Hernandez CP, Morrow K, Velasco C, et al. Effects of cigarette smoke extract on primary activated T cells. Cell Immunol. 2013;282(1):38-43.
51. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-384.